Which has stronger earnings and valuation, BSX or STE?

Boston Scientific has higher revenue and earnings than STERIS. Boston Scientific is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Boston Scientific $20.61B 3.27 $2.90B $2.39 18.98 STERIS $5.94B 3.31 $782.30M $7.93 25.45

Does the media refer more to BSX or STE?

In the previous week, Boston Scientific had 38 more articles in the media than STERIS. MarketBeat recorded 45 mentions for Boston Scientific and 7 mentions for STERIS. Boston Scientific's average media sentiment score of 1.40 beat STERIS's score of 1.00 indicating that Boston Scientific is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Boston Scientific 37 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 4 Very Negative mention(s) Positive STERIS 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EW or STE?

In the previous week, Edwards Lifesciences had 12 more articles in the media than STERIS. MarketBeat recorded 19 mentions for Edwards Lifesciences and 7 mentions for STERIS. Edwards Lifesciences' average media sentiment score of 1.02 beat STERIS's score of 1.00 indicating that Edwards Lifesciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edwards Lifesciences 13 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive STERIS 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer STE or IDXX?

In the previous week, STERIS had 5 more articles in the media than IDEXX Laboratories. MarketBeat recorded 7 mentions for STERIS and 2 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.32 beat STERIS's score of 1.00 indicating that IDEXX Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEXX Laboratories 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer STE or BDX?

In the previous week, Becton, Dickinson and Company had 13 more articles in the media than STERIS. MarketBeat recorded 20 mentions for Becton, Dickinson and Company and 7 mentions for STERIS. Becton, Dickinson and Company's average media sentiment score of 1.42 beat STERIS's score of 1.00 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Becton, Dickinson and Company 17 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, STE or DXCM?

DexCom has lower revenue, but higher earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio STERIS $5.94B 3.31 $782.30M $7.93 25.45 DexCom $4.66B 5.69 $836.30M $2.34 29.38

Is STE or DXCM more profitable?

DexCom has a net margin of 19.31% compared to STERIS's net margin of 13.18%. DexCom's return on equity of 33.33% beat STERIS's return on equity. Company Net Margins Return on Equity Return on Assets STERIS 13.18% 14.15% 9.52% DexCom 19.31% 33.33% 13.19%

Does the media prefer STE or DXCM?

In the previous week, DexCom had 21 more articles in the media than STERIS. MarketBeat recorded 28 mentions for DexCom and 7 mentions for STERIS. DexCom's average media sentiment score of 1.03 beat STERIS's score of 1.00 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 18 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

STERIS (STE) Competitors

$201.80 +1.40 (+0.70%)

As of 03:40 PM Eastern

Compare

STE vs. BSX, EW, IDXX, BDX, and DXCM

Should you buy STERIS stock or one of its competitors? MarketBeat compares STERIS with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with STERIS include Boston Scientific (BSX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), Becton, Dickinson and Company (BDX), and DexCom (DXCM). These companies are all part of the "health care equipment" industry.

How does STERIS compare to Boston Scientific?

Boston Scientific (NYSE:BSX) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 0.3% of Boston Scientific shares are held by company insiders. Comparatively, 1.1% of STERIS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Boston Scientific has a net margin of 17.29% compared to STERIS's net margin of 13.18%. Boston Scientific's return on equity of 19.17% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boston Scientific	17.29%	19.17%	10.77%
STERIS	13.18%	14.15%	9.52%

Boston Scientific has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, STERIS has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

In the previous week, Boston Scientific had 38 more articles in the media than STERIS. MarketBeat recorded 45 mentions for Boston Scientific and 7 mentions for STERIS. Boston Scientific's average media sentiment score of 1.40 beat STERIS's score of 1.00 indicating that Boston Scientific is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Boston Scientific	37 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	4 Very Negative mention(s)	Positive
STERIS	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Boston Scientific has higher revenue and earnings than STERIS. Boston Scientific is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boston Scientific	$20.61B	3.27	$2.90B	$2.39	18.98
STERIS	$5.94B	3.31	$782.30M	$7.93	25.45

Boston Scientific currently has a consensus price target of $85.08, suggesting a potential upside of 87.52%. STERIS has a consensus price target of $278.00, suggesting a potential upside of 37.76%. Given Boston Scientific's stronger consensus rating and higher probable upside, equities analysts clearly believe Boston Scientific is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boston Scientific	1 Sell rating(s)	5 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.80
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Boston Scientific beats STERIS on 11 of the 17 factors compared between the two stocks.

How does STERIS compare to Edwards Lifesciences?

Edwards Lifesciences (NYSE:EW) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

In the previous week, Edwards Lifesciences had 12 more articles in the media than STERIS. MarketBeat recorded 19 mentions for Edwards Lifesciences and 7 mentions for STERIS. Edwards Lifesciences' average media sentiment score of 1.02 beat STERIS's score of 1.00 indicating that Edwards Lifesciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edwards Lifesciences	13 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edwards Lifesciences has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, STERIS has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Edwards Lifesciences currently has a consensus target price of $95.96, suggesting a potential upside of 10.89%. STERIS has a consensus target price of $278.00, suggesting a potential upside of 37.76%. Given STERIS's higher probable upside, analysts plainly believe STERIS is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	0 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.81
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Edwards Lifesciences has a net margin of 17.39% compared to STERIS's net margin of 13.18%. Edwards Lifesciences' return on equity of 15.19% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	17.39%	15.19%	11.71%
STERIS	13.18%	14.15%	9.52%

Edwards Lifesciences has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$6.30B	7.90	$1.07B	$1.88	46.03
STERIS	$5.94B	3.31	$782.30M	$7.93	25.45

79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 0.3% of Edwards Lifesciences shares are held by company insiders. Comparatively, 1.1% of STERIS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Edwards Lifesciences beats STERIS on 12 of the 17 factors compared between the two stocks.

How does STERIS compare to IDEXX Laboratories?

STERIS (NYSE:STE) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

STERIS has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market.

STERIS presently has a consensus price target of $278.00, suggesting a potential upside of 37.76%. IDEXX Laboratories has a consensus price target of $751.00, suggesting a potential upside of 38.94%. Given IDEXX Laboratories' higher possible upside, analysts plainly believe IDEXX Laboratories is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64

IDEXX Laboratories has lower revenue, but higher earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.31	$782.30M	$7.93	25.45
IDEXX Laboratories	$4.30B	9.91	$1.06B	$13.58	39.80

IDEXX Laboratories has a net margin of 24.63% compared to STERIS's net margin of 13.18%. IDEXX Laboratories' return on equity of 70.87% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.18%	14.15%	9.52%
IDEXX Laboratories	24.63%	70.87%	32.56%

94.7% of STERIS shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 1.1% of STERIS shares are held by insiders. Comparatively, 0.8% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, STERIS had 5 more articles in the media than IDEXX Laboratories. MarketBeat recorded 7 mentions for STERIS and 2 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.32 beat STERIS's score of 1.00 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEXX Laboratories	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

IDEXX Laboratories beats STERIS on 11 of the 16 factors compared between the two stocks.

How does STERIS compare to Becton, Dickinson and Company?

STERIS (NYSE:STE) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

STERIS pays an annual dividend of $2.52 per share and has a dividend yield of 1.2%. Becton, Dickinson and Company pays an annual dividend of $4.20 per share and has a dividend yield of 2.9%. STERIS pays out 31.8% of its earnings in the form of a dividend. Becton, Dickinson and Company pays out 106.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. STERIS has raised its dividend for 20 consecutive years and Becton, Dickinson and Company has raised its dividend for 53 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

STERIS has a net margin of 13.18% compared to Becton, Dickinson and Company's net margin of 5.33%. Becton, Dickinson and Company's return on equity of 15.37% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.18%	14.15%	9.52%
Becton, Dickinson and Company	5.33%	15.37%	7.11%

94.7% of STERIS shares are held by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are held by institutional investors. 1.1% of STERIS shares are held by company insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

STERIS has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Becton, Dickinson and Company has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

Becton, Dickinson and Company has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.31	$782.30M	$7.93	25.45
Becton, Dickinson and Company	$21.84B	1.82	$1.68B	$3.95	36.57

In the previous week, Becton, Dickinson and Company had 13 more articles in the media than STERIS. MarketBeat recorded 20 mentions for Becton, Dickinson and Company and 7 mentions for STERIS. Becton, Dickinson and Company's average media sentiment score of 1.42 beat STERIS's score of 1.00 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Becton, Dickinson and Company	17 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

STERIS presently has a consensus price target of $278.00, suggesting a potential upside of 37.76%. Becton, Dickinson and Company has a consensus price target of $181.00, suggesting a potential upside of 25.30%. Given STERIS's stronger consensus rating and higher probable upside, research analysts clearly believe STERIS is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

STERIS beats Becton, Dickinson and Company on 10 of the 19 factors compared between the two stocks.

How does STERIS compare to DexCom?

STERIS (NYSE:STE) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

DexCom has lower revenue, but higher earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.31	$782.30M	$7.93	25.45
DexCom	$4.66B	5.69	$836.30M	$2.34	29.38

94.7% of STERIS shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.1% of STERIS shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

DexCom has a net margin of 19.31% compared to STERIS's net margin of 13.18%. DexCom's return on equity of 33.33% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.18%	14.15%	9.52%
DexCom	19.31%	33.33%	13.19%

STERIS has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, DexCom has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

In the previous week, DexCom had 21 more articles in the media than STERIS. MarketBeat recorded 28 mentions for DexCom and 7 mentions for STERIS. DexCom's average media sentiment score of 1.03 beat STERIS's score of 1.00 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	18 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

STERIS currently has a consensus target price of $278.00, indicating a potential upside of 37.76%. DexCom has a consensus target price of $84.88, indicating a potential upside of 23.46%. Given STERIS's higher possible upside, equities analysts clearly believe STERIS is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

DexCom beats STERIS on 13 of the 17 factors compared between the two stocks.

Get STERIS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STE vs. The Competition

Export

Metric	STERIS	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$19.67B	$6.99B	$6.48B	$23.12B
Dividend Yield	1.24%	1.25%	2.68%	4.06%
P/E Ratio	25.45	48.20	24.66	31.02
Price / Sales	3.31	46.61	529.89	20.86
Price / Cash	13.34	25.66	27.92	18.65
Price / Book	2.75	7.14	10.84	4.65
Net Income	$782.30M	$159.20M	$3.56B	$1.07B
7 Day Performance	-2.34%	-1.31%	1.71%	-1.12%
1 Month Performance	-6.87%	-1.90%	0.48%	0.10%
1 Year Performance	-14.83%	7.67%	32.98%	24.24%

STERIS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STE STERIS	4.9094 of 5 stars	$201.80 +0.7%	$278.00 +37.8%	-15.0%	$19.67B	$5.94B	25.45	17,937	Positive News
BSX Boston Scientific	4.9624 of 5 stars	$46.69 -0.5%	$85.08 +82.2%	-56.3%	$69.72B	$20.07B	19.53	59,000	Trending News Options Volume
EW Edwards Lifesciences	3.5146 of 5 stars	$86.27 +1.4%	$95.96 +11.2%	+16.2%	$49.01B	$6.07B	45.89	16,000	Positive News
IDXX IDEXX Laboratories	3.7287 of 5 stars	$570.00 +1.6%	$751.00 +31.8%	+4.2%	$44.24B	$4.30B	41.97	11,000
BDX Becton, Dickinson and Company	4.938 of 5 stars	$145.61 -0.4%	$182.73 +25.5%	-16.7%	$40.30B	$21.84B	36.86	72,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:STE) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

STERIS (STE) Competitors

STE vs. BSX, EW, IDXX, BDX, and DXCM

How does STERIS compare to Boston Scientific?

Summary

How does STERIS compare to Edwards Lifesciences?

Summary

How does STERIS compare to IDEXX Laboratories?

Summary

How does STERIS compare to Becton, Dickinson and Company?

Summary

How does STERIS compare to DexCom?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STE vs. The Competition

STERIS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

STERIS (STE) Competitors

STE vs. BSX, EW, IDXX, BDX, and DXCM

How does STERIS compare to Boston Scientific?

Do insiders & institutionals believe in BSX or STE?

Is BSX or STE more profitable?

Which has more volatility and risk, BSX or STE?

Does the media refer more to BSX or STE?

Which has stronger earnings and valuation, BSX or STE?

Do analysts rate BSX or STE?

Summary

How does STERIS compare to Edwards Lifesciences?

Does the media favor EW or STE?

Which has more volatility and risk, EW or STE?

Do analysts prefer EW or STE?

Is EW or STE more profitable?

Which has higher earnings & valuation, EW or STE?

Do institutionals & insiders hold more shares of EW or STE?

Summary

How does STERIS compare to IDEXX Laboratories?

Which has more volatility and risk, STE or IDXX?

Do analysts prefer STE or IDXX?

Which has preferable earnings & valuation, STE or IDXX?

Is STE or IDXX more profitable?

Do insiders & institutionals believe in STE or IDXX?

Does the media prefer STE or IDXX?

Summary

How does STERIS compare to Becton, Dickinson and Company?

Is STE or BDX a better dividend stock?

Is STE or BDX more profitable?

Do insiders & institutionals have more ownership in STE or BDX?

Which has more volatility & risk, STE or BDX?

Which has preferable valuation and earnings, STE or BDX?

Does the media prefer STE or BDX?

Do analysts rate STE or BDX?

Summary

How does STERIS compare to DexCom?

Which has better valuation & earnings, STE or DXCM?

Do insiders and institutionals have more ownership in STE or DXCM?

Is STE or DXCM more profitable?

Which has more risk & volatility, STE or DXCM?

Does the media prefer STE or DXCM?

Do analysts recommend STE or DXCM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STE vs. The Competition

STERIS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools